Experimental combo targets Hard-to-Treat brain cancers
NCT ID NCT07243470
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two drugs—tarlatamab and temozolomide—in adolescents and adults with high-grade brain tumors that have a specific marker called DLL3. The goal is to see if the combination is safe and can shrink tumors. About 70 participants will be enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tarlatamab and temozolomide
What this could lead to
If successful, this combination could offer a new treatment option for people with aggressive brain tumors that express DLL3.
What could go wrong
This is an early-phase trial with only 70 participants, so results may not apply to everyone. The combination may cause serious side effects, and it is not yet known if it will shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Bordeaux
NOT_YET_RECRUITINGBordeaux, 33000, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Léon Bérard
RECRUITINGLyon, 69373, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Oscar Lambret
NOT_YET_RECRUITINGLille, 59000, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Neurologique Pierre Wertheimer
RECRUITINGBron, 69677, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Saint-André
NOT_YET_RECRUITINGBordeaux, 33075, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Universitaire d'Angers
NOT_YET_RECRUITINGAngers, 49933, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital de la Timone - service adulte
RECRUITINGMarseille, 13005, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital de la Timone - service pédiatrie
RECRUITINGMarseille, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix
NOT_YET_RECRUITINGParis, 75013, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
IUCT - Claudius Regaud
RECRUITINGToulouse, 31100, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Gustave Roussy
NOT_YET_RECRUITINGVillejuif, 94085, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut de Cancérologie de l'Ouest
RECRUITINGAngers, 49055, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••